Merck Halts Development of Nemtabrutinib After Late-Stage Safety Concerns, Impacting $2.7 Billion Acquisition
Trendline US

Merck Halts Development of Nemtabrutinib After Late-Stage Safety Concerns, Impacting $2.7 Billion Acquisition

What's Happening? Merck has announced the discontinuation of its entire nemtabrutinib development program, including three Phase 3 studies, due to identified safety risks. Nemtabrutinib, also known as MK-1026, is an experimental oral BTK inhibitor that was the central asset acquired in Merck's $2.7
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.